The Burns Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Burns Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Burns Market.
Some of the key takeaways from the Burns Pipeline Report:
- Companies across the globe are diligently working toward developing novel Burns treatment therapies with a considerable amount of success over the years.
- Burns companies working in the treatment market are NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc., CUTISS AG, and others, are developing therapies for the Burns treatment
- Emerging Burns therapies such as – NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkin™, and others are expected to have a significant impact on the Burns market in the coming years.
- In June 2022, CUTISS is pleased to announce that a tissue graft patent has been granted by the European Patent Office for the personalized bioengineered human skin tissue therapy developed by CUTISS. The patent (3174563) has been granted pursuant to Article 97(1) EPC to University of Zurich (UZH)
- In December 2021, CUTISS’s first onsite manufacturing facility in Schlieren, Zurich, has received the certification of compliance for Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) from the regulatorSwissmedic, the Swiss Agency for Therapeutic Products
Burns Overview
Burns is an injury characterized by the damage to the skin as a result from the from heat, overexposure to the sun or other radiation, or chemical or electrical contact. Depending on the severity, it can be minor medical problems or life-threatening emergencies.
Get a Free Sample PDF Report to know more about Burns Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/burns-pipeline-insight
Emerging Burns Drugs Under Different Phases of Clinical Development Include:
- NMT-cNP8: NeoMatrix Therapeutics, Inc.
- TOP-N44: Topadur
- PXS-6302: Pharmaxis Ltd
- NMT- cP12: NeoMatrix Therapeutics, Inc
- MW-III: Skingenix, Inc.
- DenovoSkin™: CUTISS AG
Route of Administration
Burns pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Burns Pipeline Therapeutics Assessment
- Burns Assessment by Product Type
- Burns By Stage and Product Type
- Burns Assessment by Route of Administration
- Burns By Stage and Route of Administration
- Burns Assessment by Molecule Type
- Burns by Stage and Molecule Type
DelveInsight’s Burns Report covers around 12+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Burns product details are provided in the report. Download the Burns pipeline report to learn more about the emerging Burns therapies
Some of the key companies in the Burns Therapeutics Market include:
Key companies developing therapies for Burns are – MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.
Burns Pipeline Analysis:
The Burns pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Burns with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Burns Treatment.
- Burns key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Burns Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Burns market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Burns drugs and therapies
Burns Pipeline Market Drivers
- Rising incidence of burns, high demand of Skin grafts, growing awareness of available treatment options are some of the important factors that are fueling the Burns Market.
Burns Pipeline Market Barriers
- However, stringent regulatory approval, high cost of treatment and other factors are creating obstacles in the Burns Market growth.
Scope of Burns Pipeline Drug Insight
- Coverage: Global
- Key Burns Companies: NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc., CUTISS AG, and others
- Key Burns Therapies: NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkin™, and others
- Burns Therapeutic Assessment: Burns current marketed and Burns emerging therapies
- Burns Market Dynamics: Burns market drivers and Burns market barriers
Request for Sample PDF Report for Burns Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Burns Report Introduction |
|
2 |
Burns Executive Summary |
|
3 |
Burns Overview |
|
4 |
Burns- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Burns Pipeline Therapeutics |
|
6 |
Burns Late Stage Products (Phase II/III) |
|
7 |
Burns Mid Stage Products (Phase II) |
|
8 |
Burns Early Stage Products (Phase I) |
|
9 |
Burns Preclinical Stage Products |
|
10 |
Burns Therapeutics Assessment |
|
11 |
Burns Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Burns Key Companies |
|
14 |
Burns Key Products |
|
15 |
Burns Unmet Needs |
|
16 |
Burns Market Drivers and Barriers |
|
17 |
Burns Future Perspectives and Conclusion |
|
18 |
Burns Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services